![日本股市逼近34年新高,外資卻因日元暴跌憂回報率“縮水”](https://i-invdn-com.investing.com/news/external-images-thumbnails/pic8bb9234e270d2a4d513126c73c9bbe9e.png)
注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Leap Therapeutics Inc是一家生物技術公司。該公司專注於開發靶向和免疫腫瘤療法。其先進的臨床候選藥物DKN-01是一種針對Dickkopf-1(DKK1)蛋白的人源化單克隆抗體。DKN-01正在為食管胃癌、婦科癌和結直腸癌患者開發。DKK1調節Wnt/β-連環蛋白和PI3激酶/AKT信號通路,促進腫瘤增殖、轉移、血管生成,並通過增強髓源性抑制細胞的活性和下調腫瘤細胞上的NK細胞配體來介導免疫抑制性腫瘤微環境。該公司的產品線包括FL-301,一種針對Claudin18.2的人源化單克隆抗體,正在為胃癌和胰腺癌患者開發。Claudin18.2調節屏障特性並促進細胞間粘附。它還有針對Claudin18.2/CD137和GDF15的臨床前抗體項目。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Douglas E. Onsi | 52 | 2011 | CFO, General Counsel, Treasurer & Secretary, President, CEO & Director |
Christopher K. Mirabelli | 67 | 2011 | Chairman |
James H. Cavanaugh | 84 | 2016 | Independent Director |
Thomas John Dietz | 57 | 2016 | Lead Independent Director |
Joseph Loscalzo | 70 | 2016 | Independent Director |
William W. Li | 58 | 2017 | Independent Director |
Carl F. Nathan | - | - | Member of Scientific Advisory Board |
David Tuveson | - | - | Member of Scientific Advisory Board |
Nissim Mashiach | 60 | 2017 | Independent Director |
Andrew B Nixon | - | 2021 | Member of Scientific Advisory Board |
Richard B. Gaynor | 73 | 2021 | Member of Scientific Advisory Board |
Eileen M. O’Reilly | - | 2022 | Member of Scientific Advisory Board |
Richard L. Schilsky | 73 | 2022 | Independent Director |
Patricia Martin | 63 | 2023 | Independent Director |
Scott Joseph Antonia | - | 2023 | Member of Scientific Advisory Board |
Christian M. Richard | 54 | 2023 | Independent Director |
Bernard M. Fine | - | 2024 | Member of Scientific Advisory Board |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核